Prognostic parameter for high risk prostate cancer patients at initial presentation
ConclusionsThe presence of IDC‐P in a needle biopsy was a prognostic factor for PFS, CSS, and OS in patients with high‐risk prostate cancer who underwent radical prostatectomy. Multimodal pre‐and/or post‐ surgical therapy may be needed when IDC‐P is found in a needle biopsy specimen. (Source: The Prostate)
Source: The Prostate - November 2, 2017 Category: Urology & Nephrology Authors: Masashi Kato, Kyosuke Kimura, Akihiro Hirakawa, Yumiko Kobayashi, Ryo Ishida, Osamu Kamihira, Tsuyoshi Majima, Yasuhito Funahashi, Naoto Sassa, Yoshihisa Matsukawa, Ryohei Hattori, Momokazu Gotoh, Toyonori Tsuzuki Tags: ORIGINAL ARTICLE Source Type: research
Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients
ConclusionsStrong association of sIL‐1RA in urine with greater body size supports it as a major molecular correlate of obesity in the urine of BPH patients. Increased urine levels of CXCL‐10, CCL5, and CCL3 were marginally associated with the scores for prostate tissue inflammation and lymphocytic infiltration. Overall, elevated urinary chemokines support that BPH is a metabolic disorder and suggest a molecular link between BPH/LUTS and prostatic inflammation. (Source: The Prostate)
Source: The Prostate - October 28, 2017 Category: Urology & Nephrology Authors: Pradeep Tyagi, Saundra S. Motley, Tatsuki Koyama, Mahendra Kashyap, Jeffrey Gingrich, Naoki Yoshimura, Jay H. Fowke Tags: ORIGINAL ARTICLE Source Type: research
Issue Information ‐ Editorial Board
(Source: The Prostate)
Source: The Prostate - October 27, 2017 Category: Urology & Nephrology Tags: Issue Information Source Type: research
Predictive value of epithelial ‐mesenchymal‐transition (EMT) signature and PARP‐1 in prostate cancer radioresistance
ConclusionsOur results suggest that EMT programming effectors, integrated with the actin cytoskeleton regulator cofilin and mesenchymal PARP‐1 expression profile provide a signature of potential predictive significance of therapeutic response to radiotherapy in a subset of prostate cancer patients. (Source: The Prostate)
Source: The Prostate - October 24, 2017 Category: Urology & Nephrology Authors: Timothy W. Stark, Patrick J. Hensley, Amanda Spear, Hong Pu, Stephen S. Strup, Natasha Kyprianou Tags: ORIGINAL ARTICLE Source Type: research
The 22Rv1 prostate cancer cell line carries mixed genetic ancestry: Implications for prostate cancer health disparities research using pre ‐clinical models
ConclusionsConsidering the mortality disparities associated with PCa, which disproportionately affect African American men, there remains a burden on the scientific community to diversify the availability of biospecimens, including cell lines, for mechanistic studies on potential biological mediators of these disparities. This study is beneficial by identifying another PCa cell line that carries substantial AFR ancestry. This finding may also open the door to new perspectives on previously published studies using this cell line. (Source: The Prostate)
Source: The Prostate - October 14, 2017 Category: Urology & Nephrology Authors: Leanne Woods ‐Burnham, Anamika Basu, Christina K. Cajigas‐Du Ross, Arthur Love, Clayton Yates, Marino De Leon, Sourav Roy, Carlos A. Casiano Tags: ORIGINAL ARTICLE Source Type: research
Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH
ConclusionsPatients classified as VHR have markedly increased rates of PSA relapse, DM, and PCSM in comparison to SHR patients, whereas UIR and SHR patients have similar prognosis. Novel therapeutic strategies are needed for patients with VHR, likely involving multimodality therapy. (Source: The Prostate)
Source: The Prostate - October 10, 2017 Category: Urology & Nephrology Authors: Zachary S. Zumsteg, Zinan Chen, Lauren E. Howard, Christopher L. Amling, William J. Aronson, Matthew R. Cooperberg, Christopher J. Kane, Martha K. Terris, Daniel E. Spratt, Howard M. Sandler, Stephen J. Freedland Tags: ORIGINAL ARTICLE Source Type: research
Issue Information ‐ Editorial Board
(Source: The Prostate)
Source: The Prostate - October 10, 2017 Category: Urology & Nephrology Tags: Issue Information Source Type: research
Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers
ConclusionsThis study provides evidence that balding status assessed at a mean age of 60 years may serve as a clinical marker for circulating sex hormone concentrations. The weak‐to‐null associations between balding status and intraprostatic sex hormones reaffirm differences in organ‐specific sex hormone metabolism, implying that other sex steroid hormone‐related factors (eg, androgen receptor) play important roles in organ‐specific androgenic actions, and that other overlapping pathways may be involved in associations between the two complex conditions. (Source: The Prostate)
Source: The Prostate - October 2, 2017 Category: Urology & Nephrology Authors: Cindy Ke Zhou, Frank Z. Stanczyk, Muhannad Hafi, Carmela C. Veneroso, Barlow Lynch, Roni T. Falk, Shelley Niwa, Eric Emanuel, Yu ‐Tang Gao, George P. Hemstreet, Ladan Zolfghari, Peter R. Carroll, Michael J. Manyak, Isabell A. Sesterhenn, Paul H. Levine, Tags: ORIGINAL ARTICLE Source Type: research
PSCA promotes prostate cancer proliferation and cell ‐cycle progression by up‐regulating c‐Myc
ConclusionsPSCA is a novel cell cycle regulator with a key role in mediating c‐Myc‐induced proliferation. PSCA may be a potential diagnostic marker and therapeutic target for patients with PCa. (Source: The Prostate)
Source: The Prostate - October 2, 2017 Category: Urology & Nephrology Authors: Ermao Li, Luhao Liu, Futian Li, Lianmin Luo, Shankun Zhao, Jiamin Wang, Ran Kang, Jintai Luo, Zhigang Zhao Tags: ORIGINAL ARTICLE Source Type: research
Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A pre ‐clinical study
ConclusionPlumbagin significantly improves the effect of ADT drugs currently used in the clinic, with few side effects in mice. (Source: The Prostate)
Source: The Prostate - October 1, 2017 Category: Urology & Nephrology Authors: Parisa Abedinpour, V éronique T. Baron, Adrian Chrastina, Gaelle Rondeau, Jennifer Pelayo, John Welsh, Per Borgström Tags: ORIGINAL ARTICLE Source Type: research
The unidirectional hypoxia ‐activated prodrug OCT1002 inhibits growth and vascular development in castrate‐resistant prostate tumors
ConclusionsThese studies provide the first evidence that OCT1002 can be an effective agent in treating hypoxic, castrate‐resistant prostate tumors, either singly or in combination with established chemotherapeutics for prostate cancer. (Source: The Prostate)
Source: The Prostate - September 25, 2017 Category: Urology & Nephrology Authors: Heather Nesbitt, Jenny Worthington, Rachel J. Errington, Laurence H. Patterson, Paul J. Smith, Stephanie R. McKeown, Declan J. McKenna Tags: ORIGINAL ARTICLE Source Type: research
High ‐Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer
ConclusionsGLO1 upregulation is linked to aggressive prostate cancers characterized by ERG fusion and PTEN deletion. The strong and independent prognostic value makes it a promising candidate for routine diagnostic applications either alone or in combination with other markers. (Source: The Prostate)
Source: The Prostate - September 20, 2017 Category: Urology & Nephrology Authors: Christoph Burdelski, Rami Shihada, Andrea Hinsch, Alexander Angerer, Cosima G öbel, Emily Friedrich, Claudia Hube‐Magg, Susanne Burdak‐Rothkamm, Martina Kluth, Ronald Simon, Christina Möller‐Koop, Guido Sauter, Franzika Büscheck, Corinna Wittmer, Tags: ORIGINAL ARTICLE Source Type: research
Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey ‐Holden Prostate Cancer Academy Meeting
This article reviews the presentations and discussions from the 2017 CHPCA Meeting in order to disseminate this knowledge and accelerate new biological understandings and advances in the treatment of patients with metastatic prostate cancer. (Source: The Prostate)
Source: The Prostate - September 19, 2017 Category: Urology & Nephrology Authors: Andrea K. Miyahira, Heather H. Cheng, Wassim Abida, Leigh Ellis, Lauren C. Harshman, Daniel E. Spratt, Jonathan W. Simons, Kenneth J. Pienta, Howard R. Soule Tags: REVIEW ARTICLE Source Type: research
Issue Information ‐ Editorial Board
(Source: The Prostate)
Source: The Prostate - September 18, 2017 Category: Urology & Nephrology Tags: Issue Information Source Type: research
Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up ‐regulation of IRF1
ConclusionsWe identified active mTOR as a novel inducer of NED, and elucidated a mechanism underlying the malignant transformation of NEPCa by recapitulating NED in vitro. (Source: The Prostate)
Source: The Prostate - September 14, 2017 Category: Urology & Nephrology Authors: Mayuko Kanayama, Toshiya Hayano, Michinori Koebis, Tatsuya Maeda, Yoko Tabe, Shigeo Horie, Atsu Aiba Tags: ORIGINAL ARTICLE Source Type: research
